We’re pleased to announce our participation in the Accelerating Leading-edge Science in ALS (ALS2) program (NOT-RM-20-019). ALS2 is a $25 million NIH Common Fund initiative to spur innovative research into the basic biology of amyotrophic lateral sclerosis (ALS) through the NIH Director’s Transformative Research Award. NIGMS encourages our community of basic scientists working on relevant processes to consider applying for this opportunity.
ALS is a devastating disease with no known cure. The development of effective therapeutics can benefit tremendously from basic ALS research that 1.) tests highly novel concepts, 2.) brings together researchers from different scientific perspectives, and 3.) applies powerful emerging technologies from a variety of disciplines.Continue reading “ALS2 Funding Opportunity: Fundamental Research in Underlying Causes of Amyotrophic Lateral Sclerosis”